LAURA BARGER
Prescription History 1427698513
Nurse Practitioner - Family in Memphis, TN


Quality Rating: 92.46 out of 100 score

NPI Status: Active since January 07, 2020

Contact Information

116 N PAULINE ST RM 5149
MEMPHIS, TN
ZIP 38104
Phone: (901) 523-8990

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for LAURA BARGER, an active Family specialist practicing in Memphis, TN. Our medical registry currently tracks 4 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 51 documented patient claims. Among these therapy options, the most frequently utilized medication is Stelara, which accounts for 14 claims alone.

Medication Index

No matching medications currently found on file.

Entyvio

Generic Formulation: VedolizumabSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 13
30-Day Fills 23.4
Days Supply 700
TN State Average Benchmarks
Peer Average Claims19.0
Peer Average 30-Day Fills30.9
Peer Average Days Supply908
Conservative Utilization

This provider writes prescriptions for this formulation 31.6% less frequently than the standard regional baseline metric for practitioners inside TN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $111,064.24 across this reporting matrix range.

Provider Avg Cost Per Claim

$8,543.40

State Avg Cost Per Claim

$8,163.20

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain bowel disorders (ulcerative colitis, Crohn's disease). In these conditions, the body's defense system (immune system) attacks healthy tissues in the gut, causing symptoms such as abdominal pain, blood in the stool, and diarrhea. Vedolizumab belongs to a class of drugs known as monoclonal antibodies. It works by blocking the actions of a certain natural substance (integrin) in the body. This helps to decrease swelling (inflammation) in the gut, which lessens symptoms and may slow or stop damage from these bowel disorders.

Pantoprazole Sodium

Generic Formulation: Pantoprazole SodiumSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 12
30-Day Fills 24.0
Days Supply 720
TN State Average Benchmarks
Peer Average Claims94.0
Peer Average 30-Day Fills198.5
Peer Average Days Supply5,727
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 87.2% less volume than the regional standard for practitioners inside TN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $216.03 across this reporting matrix range.

Provider Avg Cost Per Claim

$18.00

State Avg Cost Per Claim

$16.18

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER.

Therapeutic Applications

Pantoprazole is used to treat certain stomach and esophagus problems (such as acid reflux). It works by decreasing the amount of acid your stomach makes. This medication relieves symptoms such as heartburn, difficulty swallowing, and cough. It helps heal acid damage to the stomach and esophagus, helps prevent ulcers, and may help prevent cancer of the esophagus. Pantoprazole belongs to a class of drugs known as proton pump inhibitors (PPIs).

Rinvoq

Generic Formulation: UpadacitinibSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
TN State Average Benchmarks
Peer Average Claims42.0
Peer Average 30-Day Fills43.6
Peer Average Days Supply1,307
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 71.4% less volume than the regional standard for practitioners inside TN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $77,395.02 across this reporting matrix range.

Provider Avg Cost Per Claim

$6,449.59

State Avg Cost Per Claim

$6,189.19

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Upadacitinib is used to treat certain types of arthritis (such as psoriatic arthritis, rheumatoid arthritis, axial spondyloarthritis). It helps decrease pain, tenderness, and swelling in the joints. Upadacitinib is also used to treat a skin condition called atopic dermatitis. It reduces swelling, itching, and redness in the skin. This medication may also be used to treat a certain bowel disease (ulcerative colitis). It helps to reduce symptoms of ulcerative colitis such as diarrhea, rectal bleeding, and stomach pain.

Stelara

Generic Formulation: UstekinumabSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 14
30-Day Fills 26.2
Days Supply 784
TN State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills43.0
Peer Average Days Supply1,267
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 51.7% less volume than the regional standard for practitioners inside TN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $402,062.26 across this reporting matrix range.

Provider Avg Cost Per Claim

$28,718.73

State Avg Cost Per Claim

$25,266.66

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A humanized monoclonal antibody that binds to IL-12 and IL-23 and is used as a DERMATOLOGIC AGENT in the treatment of patients with plaque PSORIASIS who have not responded to other therapies.

Therapeutic Applications

Ustekinumab is used to treat plaque psoriasis, a certain type of arthritis (psoriatic arthritis), or certain bowel conditions (Crohn's disease, ulcerative colitis). It works by blocking certain natural proteins in your body (interleukin-12 and interleukin-23) that cause inflammation (swelling) in these conditions. Ustekinumab does not cure these diseases, but helps to lessen symptoms of the disease. It can help to decrease the amount of plaques in plaque psoriasis, decrease the number of swollen/painful joints in psoriatic arthritis, and decrease symptoms such as abdominal pain/cramping and diarrhea in Crohn's disease and ulcerative colitis.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like LAURA BARGER provides transparency into local medical care patterns within Memphis, TN.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Family** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.